Quantcast
Last updated on April 23, 2014 at 15:23 EDT

Latest Fluocinolone/hydroquinone/tretinoin Stories

2014-01-15 08:29:01

FORT WORTH, Texas, Jan. 15, 2014 /PRNewswire/ -- Humberto C. Antunes, Galderma worldwide CEO, will receive a "Lifetime in Dermatology Achievement Award" from the Journal of Drugs in Dermatology (JDD) at the upcoming Orlando Dermatology Aesthetic & Clinical Conference (ODAC). The event is January 17-20, 2014, at the Omni Orlando Resort at ChampionsGate in Florida. The ODAC is a distinguished event that delivers a comprehensive report on the practice of dermatology for...

2014-01-08 12:30:22

LAUSANNE, Switzerland, Jan. 8, 2014 /PRNewswire/ -- Galderma S.A. announced today that the Nomination and Compensation Committee of Galderma Pharma S.A. appointed industry veteran Stuart Raetzman to Chief Executive Officer of Galderma Laboratories, L.P. and Vice President North America, effective March 1, 2014. Raetzman was also elected to the company's Global Executive Committee. Raetzman will report directly to Humberto C. Antunes, President and CEO of Galderma S.A. Stuart Raetzman...

2013-10-03 08:30:32

To give children with serious skin diseases the chance to be kids FORT WORTH, Texas, Oct. 3, 2013 /PRNewswire/ -- Galderma Laboratories, L.P., makers of Cetaphil®, the #1 dermatologist-recommended line of cleansers and moisturizers, will once again partner with Camp Wonder by donating a portion of the proceeds of a special-edition Moisturizing Cream, available exclusively at CVS/pharmacy locations nationwide and online at www.cvs.com/campwonder beginning in October. Over the past...

2013-04-25 08:34:51

SCHAUMBURG, Ill. and SOPHIA ANTIPOLIS, FRANCE, April 25, 2013 /PRNewswire/ -- The American Academy of Dermatology (Academy), in partnership with Galderma Research & Development, SNC is pleased to announce the creation of the American Academy of Dermatology Translational Biotechnology Fellowship. The new fellowship will offer a dermatologist the opportunity to work in drug development and translational medical research at Galderma's R&D facility located in Sophia Antipolis, France....

2013-04-23 08:33:26

MISSISSAUGA, ON, April 23, 2013 /PRNewswire/ - Nuvo Research Inc. (TSX: NRI), a specialty pharmaceutical company dedicated to building a portfolio of products for the topical treatment of pain and Galderma Pharma, S.A. (Galderma), today announced the European launch of Pliaglis (lidocaine and tetracaine) Cream 7%/7%.  Nuvo has licensed worldwide marketing rights for Pliaglis to Galderma, a global pharmaceutical company specialized in dermatology.  Marketing licenses have been...

2013-03-11 08:27:05

MISSISSAUGA, ON, March 11, 2013 /PRNewswire/ - Nuvo Research Inc. (TSX: NRI), a specialty pharmaceutical company dedicated to building a portfolio of products for the topical treatment of pain and Galderma Laboratories, L.P., the U.S. affiliate of Galderma Pharma, S.A. (Galderma), today announced the U.S. launch of Pliaglis (lidocaine and tetracaine) Cream 7%/7%.  Nuvo has licensed worldwide marketing rights for Pliaglis to Galderma, a global pharmaceutical company specialized in...

2013-02-12 08:31:30

FORT WORTH, Texas, Feb. 12, 2013 /PRNewswire/ -- Galderma Laboratories, L.P.'s Tri-Luma(® )(fluocinolone acetonide 0.01%, hydroquinone 4%, tretinoin 0.05%) Cream, the only FDA-approved triple combination topical product indicated for the short-term (up to 8 weeks) treatment of moderate to severe melasma of the face, is now available to the more than 7 million people who suffer from this chronic skin condition. Tri-Luma(® )Cream contains a clinically-proven formula which...